OBJECTIVE: To determine the frequency and severity of acute @entity137 of pelvic radiotherapy for gynecological @entity5 . STUDY DESIGN: Acase series. PLACE AND DURATION OF STUDY: Department of Oncology, The Aga Khan University Hospital, Karachi, from March 2011 to June 2012. METHODOLOGY: Atotal of 99 @entity1 with histologically proven uterine and @entity5 , receiving radiation therapy, were enrolled into the study after informed consent on justification of inclusion and exclusion criteria. @entity1 were evaluated for the frequency and severity of pelvic radiotherapy_rsquo;s side effects according to @entity137 criteria based on RTOG/EORTC and CTC version 2 criteria at the start, during and at the end of treatment. The data was analyzed by using SPSS version 16. RESULTS: Out of the 99 enrolled @entity1 , 58 (58.6%) had uterine and 41 (41.4%) had @entity5 . Mean age was 54.54 _plusmn;10.29 years. Thirty-five (35.4%) @entity1 received chemotherapy with @entity138 . Mean RTdose was 60.72 _plusmn;7.15 Gy. The most common gastrointestinal adverse effect was @entity294 in 64 (64.6%) followed by @entity4272 in 55 (55.5%), @entity390 in 33 (33.3%) and @entity391 in 16 (16.2%) @entity1 . Grade (G) 1 was the most frequently observed severity. The most common hematological @entity137 was @entity417 in 37.8% (n=31/82) {(G1=18 (21.9%), G2=11 (13.4%), G3=2 (2.4%)} followed by @entity882 in 22.8% (21/92) {( @entity48174 (17.3%), G2=2 (2.1%), G3=3 (3.2%)} and @entity1398 in 21 (21.2%) {(G1=12 (12.1%), G2=5 (5%), G3=3 (3%), @entity68822 (1%)}. Urinary @entity137 was observed in 49 (49.5%) @entity1 . On stratification, chemotherapy and higher RTdose were strong predictor of increased hematological and upper @entity344 (p < 0.05) and age > 60 years for @entity294 (p < 0.05). CONCLUSION: The frequency and severity of acute @entity137 of pelvic radiotherapy in @entity1 with @entity5 was found intermediate to high.

Frequency and Severity of Acute @entity137 of Pelvic Radiotherapy for Gynecological XXXX .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'women'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity390 :: ('MESH:D009325', 'Disease') :: ['nausea'] @entity417 :: ('MESH:D000740', 'Disease') :: ['anemia'] @entity882 :: ('MESH:D013921', 'Disease') :: ['thrombocytopenia'] @entity138 :: ('MESH:C563738', 'Disease') :: ['RT'] @entity5 :: ('MESH:D009369', 'Disease') :: ['gynecologic cancers', 'cancer', 'cervical cancer'] @entity4272 :: ('MESH:D011349', 'Disease') :: ['proctitis'] @entity294 :: ('MESH:D003967', 'Disease') :: ['diarrhea'] @entity391 :: ('MESH:D014839', 'Disease') :: ['vomiting'] @entity344 :: ('MESH:D005767', 'Disease') :: ['gastrointestinal toxicity'] @entity1398 :: ('MESH:D009503', 'Disease') :: ['neutropenia'] @entity48174 :: ('6167', 'Gene') :: ['G1=16'] @entity68822 :: ('55012', 'Gene') :: ['G4=1']
@entity5 :: (MESH:D009369,Disease) :: ['Cancer']
